Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 155.65 USD 0.73%
Market Cap: 374.7B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Johnson & Johnson
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Accounts Payable
$9B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Accounts Payable
$3.5B
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
3%
Pfizer Inc
NYSE:PFE
Accounts Payable
$5.1B
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
6%
Merck & Co Inc
NYSE:MRK
Accounts Payable
$3.6B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
5%
Zoetis Inc
NYSE:ZTS
Accounts Payable
$404m
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accounts Payable
$2.9B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
11%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
374.7B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability. For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.

JNJ Intrinsic Value
160.98 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Accounts Payable?
Accounts Payable
9B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Accounts Payable amounts to 9B USD.

What is Johnson & Johnson's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
3%

Over the last year, the Accounts Payable growth was 7%.

Back to Top